First and final report of a phase II study of the poly(ADP-ribose) polymerase (PARP) inhibitor, AGO14699, in combination with temozolomide (TMZ) in patients with metastatic malignant melanoma (MM)

R. Plummer; P. Lorigan; J. Evans; N. Steven; M. Middleton; R. Wilson; K. Snow; R. Dewji; H. Calvert

First and final report of a phase II study of the poly(ADP-ribose) polymerase (PARP) inhibitor, AGO14699, in combination with temozolomide (TMZ) in patients with metastatic malignant melanoma (MM)

R. Plummer, P. Lorigan, J. Evans, N. Steven, M. Middleton, R. Wilson, K. Snow, R. Dewji, H. Calvert

Classics, Ancient History and Archaeology

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Pages (from-to)	456S-456S
Number of pages	1
Journal	Journal of Clinical Oncology
Volume	24
Issue number	18
Publication status	Published - 20 Jun 2006
Event	42nd Annual Meeting of the American-Society-of-Clinical-Oncology - Atlanta, United States Duration: 2 Jun 2006 → 6 Jun 2006

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{2a16a941ec4143f69f5f111286d744e0,

title = "First and final report of a phase II study of the poly(ADP-ribose) polymerase (PARP) inhibitor, AGO14699, in combination with temozolomide (TMZ) in patients with metastatic malignant melanoma (MM)",

author = "R. Plummer and P. Lorigan and J. Evans and N. Steven and M. Middleton and R. Wilson and K. Snow and R. Dewji and H. Calvert",

year = "2006",

month = jun,

day = "20",

language = "English",

volume = "24",

pages = "456S--456S",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "Lippincott Williams & Wilkins",

number = "18",

note = "42nd Annual Meeting of the American-Society-of-Clinical-Oncology ; Conference date: 02-06-2006 Through 06-06-2006",

}

First and final report of a phase II study of the poly(ADP-ribose) polymerase (PARP) inhibitor, AGO14699, in combination with temozolomide (TMZ) in patients with metastatic malignant melanoma (MM). / Plummer, R.; Lorigan, P.; Evans, J. et al.
In: Journal of Clinical Oncology, Vol. 24, No. 18, 20.06.2006, p. 456S-456S.

Research output: Contribution to journal › Meeting Abstract › peer-review

TY - JOUR

T1 - First and final report of a phase II study of the poly(ADP-ribose) polymerase (PARP) inhibitor, AGO14699, in combination with temozolomide (TMZ) in patients with metastatic malignant melanoma (MM)

AU - Plummer, R.

AU - Lorigan, P.

AU - Evans, J.

AU - Steven, N.

AU - Middleton, M.

AU - Wilson, R.

AU - Snow, K.

AU - Dewji, R.

AU - Calvert, H.

PY - 2006/6/20

Y1 - 2006/6/20

UR - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=WOS_CPL&KeyUT=WOS:000239009403125&KeyUID=WOS:000239009403125

M3 - Meeting Abstract

SN - 0732-183X

VL - 24

SP - 456S-456S

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 18

T2 - 42nd Annual Meeting of the American-Society-of-Clinical-Oncology

Y2 - 2 June 2006 through 6 June 2006

ER -

First and final report of a phase II study of the poly(ADP-ribose) polymerase (PARP) inhibitor, AGO14699, in combination with temozolomide (TMZ) in patients with metastatic malignant melanoma (MM)

UN SDGs

Other files and links

Cite this